Access Pharmaceuticals has signed a collaborative agreement with bioRASI to facilitate clinical development for its Cobalamin-based oral insulin and other products.
The partners will focus on conducting a first-in-man study for oral insulin and confirming the oral bioavailability.
bioRASI will utilise its translational clinical development process, which can generate human proof-of-principle data quickly and cost effectively.
bioRasi will conduct the preclinical and clinical studies in Russia and follow guidelines to support regulatory submissions in Europe, Japan and the US.
Access will also receive assistance from bioRASI in finding partners in Russia, CIS and other eastern European countries.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData